Rene Lerer and Daniel Kazado to Join Immune Pharmaceuticals Board of Directors [Professional Services Close - Up]
(Professional Services Close - Up Via Acquire Media NewsEdge) Immune Pharmaceuticals Inc. announced that Rene Lerer, Executive Chairman of Magellan Health Services, and Daniel Kazado, Senior Advisor to Melini Capital, have agreed to join the Company's Board of Directors.
According to a release, Lerer and Kazado replace Pierre Albouy and Herve de Kergrohen, who have resigned from the board but will continue as strategic advisors to the Company. The Company's Board of Directors will continue to consist of a total of seven members.
Daniel Teper, Immune Pharmaceuticals' Chairman and CEO, said, "We are privileged to have an experienced and committed Board of Directors to provide Immune with corporate governance, and strategic, financial and operational guidance. Immune's directors have a track record of helping create significant value for shareholders of fast growing companies in the biotech and healthcare industries."
"I am very enthusiastic about joining the Board of Directors of Immune Pharmaceuticals and in helping the Company achieve its objectives," said Lerer. "As a doctor and a health care executive, I believe strongly in the Company's personalized approach to treating and developing therapeutics to help patients with inflammatory diseases and cancer. These are serious medical issues and Immune is taking an innovative approach by developing highly targeted antibodies to improve the lives of patients."
The Company also announced that the Board of Directors named the following members to lead roles with respect to its governance and committees:
-David Sidransky has been named Vice Chairman of the Board of Directors and Lead Independent Director. Sidransky is the former Vice Chairman of the Board of Imclone Systems (acquired by Eli Lilly), the Chairman of Champions Oncology, a director of Rosetta Genomics and a Professor of Medicine at John Hopkins University;
-Ana Stancic has been named Chair of the Audit Committee. Stancic was Audit Chair at Champions Oncology and held senior financial executive positions at public and private companies including Imclone Systems, Omrix (acquired by Johnson & Johnson) and Enzon;
-Isaac Kobrin has been named Chair of the Research and Development Committee. Kobrin is the former Chief Medical Officer of Actelion;
-Rene Lerer has been named Chair of the Governance and Nomination Committee.
Immune Pharmaceuticals Inc. applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer.
((Comments on this story may be sent to email@example.com))
(c) 2013 ProQuest Information and Learning Company; All Rights Reserved.
[ Back To Technology News's Homepage ]